The Seattle area is home to a new nimble drug manufacturing facility built by Just – Evotec Biologics that was unveiled Wednesday in an opening ceremony at the 130,000 square-foot… Read More
At home and at work, Justine Dell’Aringa is up for a challenge. The scientific associate director of Translational Research for Bristol Myers Squibb’s Immuno-Oncology and Cell Therapy Thematic Research Center… Read More
Shares of Absci surged more than 30% on Thursday as the Vancouver, Wash.-based biotech company made its debut as a public company. Absci priced its stock at $16 per share… Read More
Shape Therapeutics, a Seattle preclinical stage biotech company developing RNA editing and gene therapy technologies, has raised $112 million. The company’s RNA editing technologies are spun out of the lab… Read More
New funding: Just seven months after announcing a $53 million Series A round, Umoja Biopharma has raised an additional $210 million in a Series B round. The company is developing… Read More
New funding: Seattle biotech startup Oisín Biotechnologies has raised a $5 million seed round. It’s currently developing preclinical therapies that target and kill damaged cells that have been biologically turned… Read More
New funding: Gene-sequencing startup TwinStrand Biosciences raised $50 million in a Series B round led by Section 32, a California-based fund focused on biotech, technology, healthcare and life sciences. Total… Read More
New funding: At a moment when vaccines are on everyone’s mind, a Seattle-based biotech company that has an unusual approach to vaccine production has raised $100 million in a Series… Read More
New funding: Outpace Bio raised a $30 million Series A investment round to design custom cell and gene-based therapies. The science: Founded in November, the Seattle startup is developing software… Read More
New funding: Eliem Therapeutics, a new Seattle biotech startup led by former Juno Therapeutics exec Bob Azelby, raised $80 million to develop clinically-validated therapies for pain and depression. The pipeline:… Read More
New funding: Vancouver, Wash.-based biotech company AbSci raised $125 million in a round led by Casdin Capital and Redmile Group. The tech: Founded in 2011, AbSci’s “Protein Printing” technology is used… Read More
New funds, new partners: Seattle’s Presage Biosciences announced $13 million in funding as well new collaborations with biotech giant Merck and California-based Maverick Therapeutics. Presage is a biotech device company… Read More
New funding: Notch Therapeutics has raised a $85 million Series A round, bringing its total funding to $91 million. The biotech company was founded in 2018 and is developing stem… Read More
New funding: Ozette, a biotech company that last year spun out of the Fred Hutchinson Cancer Research Center and was incubated at the Allen Institute for Artificial Intelligence (AI2), has… Read More
Less than three years after it was founded and with no revenue on the books, Sana Biotechnology filed to go public on Wednesday in what would be the latest Seattle… Read More
University of Washington biotech spinout Opticyte has landed $2.9 million in federal grants and $1.7 million in seed funding. The Seattle startup is developing a non-invasive technology that can detect… Read More
Sujal Patel is getting the band back together at his secretive new biotech startup Nautilus Biotechnology. The company is beefing up its executive team with three new additions: Chris Blessington,… Read More
Silverback Therapeutics will raise $241.5 million as the Seattle biotech company goes public Friday. Silverback priced its IPO on Thursday evening at $21 per share, which exceeded the high end… Read More
Washington State University is launching a new life sciences incubator in Spokane, Wash., designed to help startups grow out of the university while also connecting regional entrepreneurs to faculty experts.… Read More
Umoja Biopharma raised $53 million to expand development of its CAR T-cell immunotherapy treatments for blood-based and organ-based tumors in adult and pediatric patients. Founded last year, the pre-clinical Seattle-based… Read More
Can a nonprofit research institution operate more effectively by taking a page from the commercial biotech industry? That’s the idea behind Seattle Children’s Therapeutics, a new effort by Seattle Children’s… Read More
Seattle biotech startup Silverback Therapeutics continues to raise capital to support development of its therapies for cancer, fibrosis, and other conditions. The company today announced a $85 million Series C round,… Read More
Athira Pharma will raise at least $204 million as the Seattle biotech startup becomes a public company on Friday. Athira priced its IPO on Thursday evening at $17 per share,… Read More
Cancer detection startup Grail today filed to go public as the Silicon Valley biotech aims to raise more funding for its blood test. The company’s backers include Microsoft co-founder Bill… Read More
Athira Pharma is aiming to go public. The Seattle biotech filed initial IPO paperwork Wednesday, a surprising move that would give the company additional capital to develop its therapies for… Read More
A researcher with ties to Seattle-based biotech company OncoSenX has received a $4.2 million grant from the Canadian Institutes of Health Research for work on a COVID-19 vaccine. John Lewis,… Read More
Chinook Therapeutics, a biotech company creating targeted therapies for kidney diseases, has agreed to merge with Berkeley, Calif.-based Aduro Biotech. The proposed all-stock deal “is a unique opportunity for Chinook… Read More
The foundation of Athira Pharma began while Leen Kawas was earning her Ph.D. in molecular pharmacology at Washington State University nearly a decade ago. Fast forward to today and the Seattle… Read More
A-Alpha Bio, a Seattle venture that began at the University of Washington, has won a $620,472 grant from the National Science Foundation to develop a system that identifies molecules capable… Read More
Seattle biotech startup Good Therapeutics raised another $11 million to create “context dependent” protein drugs that act only when needed. The 4-year-old company is developing cytokines that regulate their own… Read More